Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$15.77 -5.8%	$14.57	$8.03 ▼ $17.75	$2.01B	1.84	1.82 million shs	1.18 million shs
IMCR Immunocore	$32.34 +0.1%	$33.45	$23.15 ▼ $39.33	$1.63B	0.77	323,903 shs	215,960 shs
KOD Kodiak Sciences	$9.48 -15.7%	$5.82	$1.92 ▼ $11.60	$594.24M	2.41	751,039 shs	923,590 shs
SPRY ARS Pharmaceuticals	$13.79 -1.7%	$16.82	$10.00 ▼ $18.90	$1.39B	0.9	1.67 million shs	2.18 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	-0.89%	+17.97%	+14.11%	+15.37%	+97.17%
IMCR Immunocore	-1.73%	+1.32%	-11.02%	-0.25%	-11.24%
KOD Kodiak Sciences	+6.43%	+40.10%	+103.80%	+177.09%	+355.47%
SPRY ARS Pharmaceuticals	-3.44%	-14.35%	-21.71%	-2.09%	+5.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARQT Arcutis Biotherapeutics	2.4993 of 5 stars	3.4	2.0	0.0	2.8	1.7	0.6
IMCR Immunocore	1.9315 of 5 stars	3.3	1.0	0.0	2.8	2.5	0.0
KOD Kodiak Sciences	3.1449 of 5 stars	2.0	1.0	4.6	2.4	3.3	0.0
SPRY ARS Pharmaceuticals	2.6228 of 5 stars	3.6	0.0	0.0	2.2	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.86	Moderate Buy	$19.80	25.55% Upside
IMCR Immunocore	2.50	Moderate Buy	$58.00	79.34% Upside
KOD Kodiak Sciences	2.00	Hold	$11.75	23.95% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	124.80% Upside

Current Analyst Ratings Breakdown

Latest KOD, ARQT, IMCR, and SPRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$3.00 ➝ $5.00
8/14/2025	KOD Kodiak Sciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underweight ➝ Underweight	$4.00 ➝ $7.00
8/14/2025	KOD Kodiak Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$15.00
8/7/2025	ARQT Arcutis Biotherapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/7/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
7/25/2025	ARQT Arcutis Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$18.00
6/2/2025	IMCR Immunocore	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
5/27/2025	IMCR Immunocore	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$65.00
5/23/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$196.54M	9.62	N/A	N/A	$1.16 per share	13.59
IMCR Immunocore	$310.20M	5.25	N/A	N/A	$7.71 per share	4.19
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$1.33 per share	N/A
SPRY ARS Pharmaceuticals	$89.15M	15.29	$0.01 per share	1,656.77	$1.95 per share	7.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$140.04M	-$0.75	N/A	N/A	N/A	-35.40%	-62.62%	-25.16%	11/5/2025 (Estimated)
IMCR Immunocore	-$51.09M	-$0.40	N/A	N/A	N/A	-5.70%	-5.40%	-1.93%	11/5/2025 (Estimated)
KOD Kodiak Sciences	-$176.21M	-$3.80	N/A	N/A	N/A	N/A	-155.27%	-63.29%	N/A
SPRY ARS Pharmaceuticals	$8M	-$0.49	N/A	N/A	N/A	-42.74%	-21.85%	-15.88%	N/A

Latest KOD, ARQT, IMCR, and SPRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	KOD Kodiak Sciences	-$1.01	-$1.03	-$0.02	-$1.03	N/A	N/A
8/13/2025	Q2 2025	SPRY ARS Pharmaceuticals	-$0.41	-$0.46	-$0.05	-$0.46	$12.92 million	$15.72 million
8/7/2025	Q2 2025	IMCR Immunocore	-$0.21	-$0.20	+$0.01	-$0.20	$122.96 million	$130.65 million
8/6/2025	Q2 2025	ARQT Arcutis Biotherapeutics	-$0.18	-$0.13	+$0.05	-$0.13	$72.70 million	$81.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.77	3.20	3.04
IMCR Immunocore	1.01	5.89	5.86
KOD Kodiak Sciences	N/A	3.48	3.48
SPRY ARS Pharmaceuticals	0.37	6.17	5.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
IMCR Immunocore	84.50%
KOD Kodiak Sciences	89.06%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
IMCR Immunocore	10.40%
KOD Kodiak Sciences	45.90%
SPRY ARS Pharmaceuticals	33.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	150	119.90 million	108.63 million	Optionable
IMCR Immunocore	320	50.39 million	45.15 million	Optionable
KOD Kodiak Sciences	90	52.82 million	28.58 million	Optionable
SPRY ARS Pharmaceuticals	90	98.83 million	65.72 million	Optionable

KOD, ARQT, IMCR, and SPRY Headlines

Recent News About These Companies

Equities Analysts Issue Forecasts for SPRY FY2025 Earnings

August 19 at 2:58 AM | marketbeat.com

Equities Analysts Offer Predictions for SPRY FY2025 Earnings

August 19 at 2:33 AM | americanbankingnews.com

Leerink Partnrs Issues Negative Forecast for SPRY Earnings

August 19 at 2:55 AM | marketbeat.com

Equities Analysts Offer Predictions for SPRY Q3 Earnings

August 19 at 2:55 AM | marketbeat.com

William Blair Issues Optimistic Forecast for SPRY Earnings

August 19 at 2:45 AM | americanbankingnews.com

Leerink Partnrs Issues Pessimistic Outlook for SPRY Earnings

August 19 at 2:45 AM | americanbankingnews.com

ARS Pharmaceuticals (NASDAQ:SPRY) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS

August 15, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q2 2025 Earnings Call Transcript

August 14, 2025 | msn.com

ARS Pharma Sales Jump 3,040% in Q2

August 14, 2025 | aol.comA

ARS Pharmaceuticals Inc (SPRY) Q2 2025 Earnings Report Preview: What To Look For

August 14, 2025 | finance.yahoo.com

ARS Pharmaceuticals Reports Strong Growth for neffy

August 14, 2025 | msn.com

ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript

August 13, 2025 | seekingalpha.com

ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates

August 13, 2025 | zacks.com

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

August 13, 2025 | globenewswire.com

Earnings Outlook For ARS Pharmaceuticals

August 12, 2025 | benzinga.com

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 6.3% - Should You Sell?

August 12, 2025 | marketbeat.com

Analysts Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) PT at $31.00

August 8, 2025 | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Holdings Raised by Levin Capital Strategies L.P.

August 6, 2025 | marketbeat.com

XTX Topco Ltd Raises Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

August 6, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Buy" by Brokerages

August 5, 2025 | marketbeat.com

Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength

August 4, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD, ARQT, IMCR, and SPRY Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$15.77 -0.97 (-5.79%)

Closing price 04:00 PM Eastern

Extended Trading

$15.58 -0.19 (-1.20%)

As of 07:46 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Immunocore NASDAQ:IMCR

$32.34 +0.03 (+0.09%)

Closing price 04:00 PM Eastern

Extended Trading

$32.32 -0.02 (-0.06%)

As of 04:10 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Kodiak Sciences NASDAQ:KOD

$9.48 -1.77 (-15.73%)

Closing price 04:00 PM Eastern

Extended Trading

$9.34 -0.14 (-1.43%)

As of 07:56 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

ARS Pharmaceuticals NASDAQ:SPRY

$13.79 -0.24 (-1.71%)

Closing price 04:00 PM Eastern

Extended Trading

$13.96 +0.18 (+1.27%)

As of 07:55 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time